Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

146

Participants

Timeline

Start Date

April 15, 2018

Primary Completion Date

December 30, 2022

Study Completion Date

June 30, 2026

Conditions

Colorectal CancerLiver Metastases

Interventions

DRUG

Irinotecan

Irinotecan 130 mg/m²

DRUG

Cetuximab

Cetuximab, iv, 500mg/m2

DRUG

5-fluorouracil

5-FU 2400 mg/m² cont. inf.

DRUG

Oxaliplatin

oxaliplatin 85 mg/m²

DRUG

Leucovorin

leucovorin 200 mg/m²

Trial Locations (1)

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors

lead

Sun Yat-sen University

OTHER

NCT03493048 - Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM | Biotech Hunter | Biotech Hunter